期刊文献+

EGFR过表达降低人子宫内膜癌细胞孕激素敏感性的研究 被引量:1

Over-expression EGFR reduced sensitivity of human endometrial carcinoma cells to progesterone
下载PDF
导出
摘要 目的:检测表皮生长因子受体(EGFR)基因在子宫内膜癌孕激素敏感细胞株Ishikawa及孕激素不敏感细胞株KLE的表达,探讨EGFR基因过表达对人子宫内膜癌细胞孕激素敏感性的影响。方法:实时定量PCR法和蛋白印迹法检测Ishikawa和KLE细胞中EGFR及PR-BmRNA和蛋白的表达。将EGFR全长cDNA真核表达质粒在脂质体介导下转染至Ishikawa细胞,同时以转染空载体和未转染的Ishikawa细胞为对照,分别应用实时定量PCR检测各组细胞EGFR、PR-BmRNA表达的变化,应用蛋白印迹法检测各组细胞EGFR、PR-B蛋白表达的变化;CCK-8法观察转染EGFR基因后Ishikawa细胞对孕激素敏感性的变化。结果:(1)Ishikawa细胞中,EGFRmRNA和蛋白的表达明显低于KLE细胞(P<0.001),而PR-BmRNA和蛋白的表达则显著高于KLE细胞(P<0.001);(2)稳定转染EGFR基因后,Ishikawa细胞中EGFRmRNA和蛋白的表达水平明显高于转染空载体和未转染的Ishikawa细胞(P<0.001),而PR-BmRNA和蛋白的表达水平则显著降低;(3)10-8、10-7、10-6、10-5mol/L的MPA对未转染和转染空载体的Ishikawa细胞的抑制作用显著(P<0.05),但对稳定过表达EGFR的Ishikawa细胞无明显抑制作用(P>0.05)。结论:转染EGFR基因能有效提高Ishikawa细胞内EGFR基因的表达,但可下调PR-B基因的表达使Ishikawa细胞对MPA不敏感。 Objective:To examine expressions of EGFR gene in endometrial carcinoma progesterone-sensitive cell line Ishikawa cells and progesterone-resistant cell line KLE cells,and evaluate the effect of over-expression EGFR gene on progesterone sensitivity of Ishikawa cells.Methods:The expressions of EGFR,PR-B mRNA and protein in Ishikawa and KLE cells were detected by real-time PCR and Western blot.Recombinant eukaryotic expression plasmid containing human hole length cDNA of EGFR gene was transfected into Ishikawa cells by lipofectamine 2000.The expressions of EGFR,PR-B mRNA were monitored by real-time PCR and the expressions of EGFR,PR-B protein were analyzed by Western blot in EGFR transfected and untransfected Ishikawa cells.Proliferation and sensitivity of cells to progesterone were measured by Cell Counting Kit-8(CCK-8).Results:(1)The expressions of EGFR mRNA and protein in Ishikawa cells were significantly lower than those in KLE cells(P0.001).However the expressions of PR-B mRNA and protein were converse(P0.001).(2)After stably transfected with EGFR gene,the expressions of EGFR mRNA and protein in Ishikawa cells were higher than those in Ishikawa cells tranfected with empty vector and untransfected Ishikawa cells(P0.001).Interestingly,the expressions of PR-B mRNA and protein in overexpression EGFR Ishikawa cells were significantly decreased(P0.001).(3)MPA treatment reduced the growth of parental Ishikawa cells and Ishikawa cells tranfected with empty vector in a dose-dependent manner:when MPA added at 10-7,10-6,10-5mol/L,the inhibitory effects were significantly respectively(P0.05).But,the inhibitory effects in over-expression EGFR Ishikawa cells were not obvious(P0.05).Conclusion:Transfection of EGFR can increase the expression of EGFR in Ishikawa cells,and decrease the sensitivity of MPA of human endometrial carcinoma cell line Ishikawa by reducing the expression of PR-B.
出处 《现代妇产科进展》 CSCD 北大核心 2009年第12期897-901,共5页 Progress in Obstetrics and Gynecology
基金 上海市科委基金资助项目(No:07ZR14059)
关键词 子宫内膜肿瘤 表皮生长因子受体 醋酸甲羟孕酮 孕激素受体B Endometrial neoplasms Epidermal growth factor receptor Medroxyprogesterone acetate Progesterone B receptor
  • 相关文献

参考文献11

  • 1Doll A, Abal M, Rigau M,et :al. Novel molecular profiles of endometrlal cancernew light through old windows [ J ]. J Steroid Biochem Mol Bioi ,2008,108:221-229.
  • 2Kaku T,Yoshikawa H,Tsuda H et al. Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women:central pathologic review and treatment outcome [ J ]. Cancer Lett, 2001, 167:39-48.
  • 3Dai D, Wolf DM, Litman ES, et al. Progesterone inhibits human endometrial cancer cell growth and invasiveness: down-regulation of cellular adhesion molecules through progesterone B receptors [ J ].Cancer Res, 2002,62 : 881 - 886.
  • 4Zhao SJ', Chen X,I, Lu X, et al. Epidermal growth factor signaling enhanced by long-term medroxyprogesterone acetate treatment in endometrial carcinoma [ J ]. Gynecol Oncol,2007 ,105 :45-54.
  • 5Leslie KK, Kumar NS, Richer J, et al. Differential expression of the A and B isoforms of progesterone receptor in human endometrial cancer cells. Only progesterone receptor B is induced by estrogen and associated with strong transcriptional activation [ J ]. Ann N Y Acad Sci ; 1997, 828 : 17-26.
  • 6Zhou YH, Tan F, Hess KR, et al. Tile expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival[ J ]. Clin Cancer Res, 2003,9: 3369-3375.
  • 7Goldman S, Shalev E. Difference in progesterone-receptor isoforms ratio between early and late first-trimester human trophoblast is lssociated with differential cell invasion and matrix metall ,roteinase 2 expression [ J]. Bio Reprod, 2006,74 : 13.
  • 8Barton J, Blaolodge G, Wakeling A. Growth factors and their receptors: new targets for prostate cancer therapy [ J ]. Urology, 2001,58 : 114-122.
  • 9Magdnlena B, Andrzeg S, Tomasz R, et al. Expression of erbB-1 and erbB-2 genes in normal and pathological human endometrium [ J ]. Oncol Rep, 2007,18 : 261-265.
  • 10王娟,滕银成.分子靶向药物用于晚期或复发子宫内膜癌的研究进展[J].现代妇产科进展,2009,18(7):548-550. 被引量:3

二级参考文献26

  • 1Doll A,Abal M,Rigau M,et al.Novel molecular profiles of endometrial cancer-new light through old windows[J].J Steroid Biochem Mol Biol,2008,108:221-229.
  • 2Leslie KK,Laidler L,Albitar L,et al.Tyrosine kinase inhibitors in endometrial cancer[J].Int J Gynecol Cancer,2005,15:409-411.
  • 3Ai ZH,Yin LH,Zhou XR,et al.Inhibition of survivin reduces cell proliferation and induces apoptosis in human endometrial cancer[J].Cancer,2006,107:746-756.
  • 4Zhao SJ,Chen X J,Lu X,et al.Epidermal growth factor signaling enhanced by long-term medroxyprogesterone acetate treatment in endometrial carcinoma[J].Gynecol Oncol,2007,105:45-54.
  • 5Magdrdena B,Andrzeg S,Tomasz R,et al.Expression of erbB-1 and erbB-2 genes in normal and pathological human endometrium[J].Oncology Rep,2007,18:261-265.
  • 6Albitar L,Pickett G,Morgan M,et al.Models representing type Ⅰ and type Ⅱ human endometrial cancers:Ishikawa H and Hec50co cells[J].Gynecol Oncol,2007,106:52-64.
  • 7Scaltriti M,Baselga J.The epidermal growthfactor receptor pathway:a model for targeted therapy[J].Clin Cancer Res,2006,12:5268-5272.
  • 8Albitar L,Carter MB,Davies S,et al.Consequences of the loss of p53,RB1,and PTEN:relationship to gefitinib resistance in endometrial cancer[J].Gynecol Oncol,2007,106:94-104.
  • 9Jasa KV,Fyles A,Elit L,et al.Phase Ⅱ study of erlotinib (OSI 774) in women with recurrent or metastatic endometrial cancer:NCIC CTG IND-148[J].Proc Am Soc Clin Oncol,2004,22:5019.
  • 10Oza AM,Eisenhauer EA,Elit L,et al.Phase Ⅱ study of erlotinib in recurrent or metastatic endometrial cancer:NCIC IND-148[J].J Clin Oncol,2008,26:4319-4325.

共引文献2

同被引文献12

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部